By Professor Michael Leonard Friedlander

Conference Papers

McKiernan CJ; SahinToth M; Friedlander M, 1997, 'The retinal rod Na+/Ca2+-K+ exchanger contains a non-cleaved signal sequence in vitro', in MOLECULAR BIOLOGY OF THE CELL, AMER SOC CELL BIOLOGY, pp. 1138 - 1138

Zalcberg JR; Bishop JF; Millward MJ; Zimet A; Laird J; Barter C; Seward D; McKeage MJ; Friedlander ML; Toner G; Berille J; Blanc C, 1995, 'Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 1084 - 1084, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995TH91901079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gonen Y; Kimmel E; TelOr E; Friedlander M, 1995, 'Intercellular assimilate translocation in Gracilaria cornea (Gracilariaceae, Rhodophyta)', in HYDROBIOLOGIA, KLUWER ACADEMIC PUBL, CHILE, VALDIVIA, pp. 421 - 428, presented at 15th International Seaweed Symposium, CHILE, VALDIVIA

SAHINTOTH M; NICOLL DA; FRANK JS; PHILIPSON KD; FRIEDLANDER M, 1995, 'THE CLEAVED N-TERMINAL SIGNAL SEQUENCE OF THE CARDIAC NA+-CA2+ EXCHANGER IS NOT REQUIRED FOR FUNCTIONAL MEMBRANE INTEGRATION', in MOLECULAR BIOLOGY OF THE CELL, AMER SOC CELL BIOL, pp. 2319 - 2319

FRIEDLANDER M; LEVY I, 1994, 'CULTIVATION OF GRACILARIA IN OUTDOOR TANKS AND PONDS', in JOURNAL OF APPLIED PHYCOLOGY, KLUWER ACADEMIC PUBL, ITALY, TRIESTE, pp. 315 - 324, presented at Workshop on Gracilaria and its Cultivation, ITALY, TRIESTE, http://dx.doi.org/10.1007/BF00004005

GONEN Y; KIMMEL E; FRIEDLANDER M, 1992, 'EFFECT OF RELATIVE WATER MOTION ON PHOTOSYNTHETIC RATE OF RED ALGA GRACILARIA-CONFERTA', in HYDROBIOLOGIA, KLUWER ACADEMIC PUBL, FRANCE, BREST, pp. 493 - 498, presented at 14TH INTERNATIONAL SEAWEED SYMP, FRANCE, BREST, 16 August 1992 - 21 August 1992

SVIRSKI E; BEER S; FRIEDLANDER M, 1992, 'GRACILARIA-CONFERTA AND ITS EPIPHYTES .2. INTERRELATIONSHIP BETWEEN THE RED SEAWEED AND ULVA CF LACTUCA', in HYDROBIOLOGIA, KLUWER ACADEMIC PUBL, FRANCE, BREST, pp. 391 - 396, presented at 14TH INTERNATIONAL SEAWEED SYMP, FRANCE, BREST, 16 August 1992 - 21 August 1992

FRIEDLANDER ML; HEDLEY DW; TAYLOR IW; TATTERSALL MHN, 1984, 'THE BIOLOGICAL SIGNIFICANCE OF CELLULAR DNA CONTENT IN OVARIAN-CANCER', in PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, pp. 34 - 34

FRIEDLANDER ML; MUSGROVE L; RUSSELL P; TOPPLIA M; HEDLEY D; TAYLOR IW; TATTERSALL MHN, 1983, 'FLOW CYTOMETRIC ANALYSIS OF DNA CONTENT IN OVARIAN-CANCER', in CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, BLACKWELL SCIENCE, pp. 489 - 489, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RB75800115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Proceedings (Editor of)

Tiller K; Meiser B; Tucker K; Andrews L; Gaff C; Kirk J; Phillips KA; Duding T; Friedlander ML, (eds.), 2003, '6th World Congress Psycho-Oncology', Banff Alberta Canada, presented at 6th World Congress Psycho-Oncology, Banff Alberta Canada, 23 April 2003 - 27 April 2003

Thewes B; Meiser B; Rickard J; Friedlander ML, (eds.), 2003, '6th World Congress Psycho-Oncology', Banff Alberta Canada, presented at 6th World Congress Psycho-Oncology, Banff Alberta Canada, 23 April 2003 - 27 April 2003

Conference Posters

Lemech CR; Friedlander M, 2009, 'Clear cell cancer of the ovary: from resistance to response', Canberra Australia, presented at MOGA Annual Scientific Meeting, Canberra Australia, 12 August 2009 - 14 August 2009, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2009.01218.x/pdf

Conference Presentations

Hayes S; Friedlander M; Obermair A; Mileshkin L; Janda M; Gordon L; Barnes E; Beesley V; Eakin E; Sommeijer D; Martyn J; Stockler M; Gebski VAL; Naumann F; Schmitz K; Webb P, 2014, 'EXERCISE DURING CHEMOTHERAPY FOR OVARIAN CANCER (ECHO): STUDY DESIGN FEATURES AND OUTCOMES OF A CANCER AUSTRALIA AND CANCER COUNCIL AUSTRALIA FUNDED RANDOMISED, CONTROLLED TRIAL', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500161&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Nahm SH; Kiely BE; O'Connell RL; Lee YC; Davis A; Avall-Lundqvist E; Berek JS; Berton D; Donnellan P; Hilpert F; Joly F; Lanceley A; Ledermann JA; Okamoto A; Oza A; Pignata S; Sehouli J; King MT; Friedlander M; Stockler MR; Roncolato FT, 2025, 'Prognostic significance and accuracy of oncologists’ estimates of survival time in recurrent ovarian cancer', in International Journal of Gynecological Cancer, Vol. 35, http://dx.doi.org/10.1016/j.ijgc.2024.100030

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol as primary prophylaxis', in Supportive Care in Cancer, Vol. 32, http://dx.doi.org/10.1007/s00520-024-08460-z

Konstantinopoulos P; Kim J-W; Freyer G; Lee J-Y; Gaba L; Grisham R; Colombo N; Wu X; Sehouli J; Cruz F; Cibula D; Monk B; Nyvang G-B; Friedlander M; Lorusso D; Van Nieuwenhuysen E; Glasspool R; Marth C; Hinson P; Zuradellit M; Wangt C; Su F; Miller M; Matulonis U; Gonzalez-Martin A, 2024, 'Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 190, pp. S12 - S12

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander ML; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Oza AM; Martin AJG; Aghajanian C; Bradley WH; Mathews C; McNamara J; Lowe E; Moore KN, 2022, 'Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S779 - S779, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.645

Deva S; Millward M; Friedlander M; Gan HK; Hovarth LG; Lee J-S; Hill A; Sandhu S; Liang L; Shi J; Zhang Y; Shi Y; Ma X; Wu X; Shen Z; Desai J, 2022, 'Abstract LB511: The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. LB511 - LB511, http://dx.doi.org/10.1158/1538-7445.am2022-lb511

Tan DSP; Choi CH; Ngoi N; Sun H; Heong V; Ow SGW; Chay WY; Kim HS; Lim YW; Goss G; Goh JC; Luo V; Tai BC; Lim D; Kaliaperumal N; Au VB; Connolly J; Kim J-W; Friedlander M; Kim K, 2022, 'A multicenter phase II randomized trial of durvalumab (D) versus physician's choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Woodford R; Zhou D; Kok P-S; Lord S; Friedlander M; Marschner I; Simes J; Lee CK, 2022, 'Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Tan DSP; Choi CH; Ngoi N; Sun H; Heong V; Ow SGW; Chay WY; Kim HS; Lim YW; Goss G; Goh JC; Luo V; Tai BC; Lim D; Kaliaperumal N; AU VB; Connolly J; Kim J-W; Friedlander M; Kim K, 2022, 'A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5565 - 5565, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5565

Woodford R; Zhou D; Kok P-S; Lord S; Friedlander M; Marschner I; Simes J; Lee CK, 2022, 'Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 6518 - 6518, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.6518

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2022, 'Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy', in Medicine & Science in Sports & Exercise, LIPPINCOTT WILLIAMS & WILKINS, San Diego, California, Vol. 54, pp. 322 - 322, presented at ACSM 2022 Annual Meeting & World Congresses, San Diego, California, 31 May 2022 - 04 June 2022, http://dx.doi.org/10.1249/01.mss.0000879060.88938.0b

Meagher NS; Hamilton PT; Anglesio MS; Harris HR; Konecny GE; Schildkraut JM; Talhouk A; Friedlander ML; Pearce CL; Pike MC; Kobel M; Doherty JA; Goode EL; Nelson BH; DeFazio A; Ramus SJ, 2022, 'Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia', in JOURNAL OF IMMUNOLOGY, AMER ASSOC IMMUNOLOGISTS, Vol. 208, http://dx.doi.org/10.4049/jimmunol.208.Supp.179.04

Trillsch F; Mahner S; Ataseven B; Asher R; Aryal N; Dubot C; Clamp A; Penson RT; Oza A; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; Denys H; Lowe ES; Lee CK; Pujade-Lauraine E, 2022, 'Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study', in Gynecologic Oncology, Vol. 165, pp. 40 - 48, http://dx.doi.org/10.1016/j.ygyno.2022.01.024

Pitiyarachchi O; Lee YC; Ramus SJ; deFazio A; Friedlander M, 2022, 'Rates of somatic variants in homologous recombination DNA repair deficiency genes in older patients with high-grade serous ovarian carcinoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 30 - 30

Simon S; Francis K; Dalrymple J; Gebski V; Lord S; Friedlander M; Lee CK, 2021, 'Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S745 - S745, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1195

Ngoi NYL; Tan TZ; Kuay KT; Tan ACY; Lee JY; Pang MY; Tham KW; Chan J; Wong WL; Chay WY; Anne D; Friedlander M; Varma S; Meniawy T; Au-Yeung G; Scott C; Mileshkin L; Bowtell D; Huang RY-J; Tan DSP, 2021, 'Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S736 - S736, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1179

Mapagu C; Srirangan S; Pattnaik S; Nevins N; Provan P; Bouantoun N; Kirk J; Chiew Y-E; Dobrovic A; Musafer A; Zhang F; Balleine R; Beale P; Bowtell D; Brand A; Friedlander M; Harnett P; Marsh D; Goli S; deFazio A, 2021, 'Assessment of HR deficiency in ovarian cancer to increase PARP inhibitor targets beyond BRCA1/2', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 54 - 55, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pavanello M; Chiew Y-E; Mapagu C; Srirangan S; Nevins N; Bouantoun N; Pattnaik S; Gao B; Kennedy CJ; Boros J; Provan P; Friedlander M; Samimi G; Brand A; Marsh DJ; Beale P; Anderson L; Bowtell DDL; Balleine RL; Harnett PR; DeFazio A, 2021, 'Cyclin E1 (CCNE1) gene amplification assessment in prospectively recruited ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 67 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gersekowski K; Jordan S; Delahunty R; Alsop K; Goode EL; Bowtell D; DeFazio A; Friedlander M; Obermair A; Grant P; Webb P, 2021, 'Impact of BRCA mutation status and lifestyle factors on survival among women with ovarian cancer', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, Vol. 50, pp. 79 - 79, http://dx.doi.org/10.1093/ije/dyab168.217

Meagher N; Koebel M; Anderson L; Tan A; Bolithon A; Anglesio M; Cohen P; Crowe P; Doherty J; Fasching P; Harris H; Hogdall E; Huntsman D; James P; Karlan B; Kelemen L; Kommoss S; Konecny G; Gorringe K; Modugno F; Park S; Pharoah P; Staebler A; Sundfeldt K; Thorne H; Wu A; DeFazio A; Friedlander M; Ramus S, 2021, 'Pattern of invasion in stage I mucinous ovarian cancer is prognostic within 2-years of diagnosis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 47 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Woodford R; Zhou D; Kok P-S; Lord S; Marschner I; Friedlander M; Lee CK, 2021, 'The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1516

Smith D; Robledo K; Yip S; Cummins M; Kok P-S; Lee YC; Friedlander M; Baron-Hay SE; Shannon CM; Coward J; Beale PJ; Goss G; Meniawy T; Lombard JM; Spurdle AB; Andrews J; Stockler MR; Mileshkin LR; Antill YC, 2021, 'Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5584

Feiglin T; Armstrong G; Sinha R; Robertson G; Friedlander M; Wan K, 2021, 'Two Cases of Intraplacental Choriocarcinoma Causing Severe Fetal Anaemia at Term', in AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, WILEY, Vol. 61, pp. 7 - 7, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000651190000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R, 2021, 'Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)', in Gynecologic Oncology, Vol. 161, pp. 160 - 165, http://dx.doi.org/10.1016/j.ygyno.2021.02.016

Bradley W; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke G; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Cain T; Lowe E; DiSilvestro P, 2021, 'Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 162, pp. S25 - S26, http://dx.doi.org/10.1016/S0090-8258(21)00694-6

Sivakumaran T; Krasovitsky M; Freimund A; Lee KC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2020, 'TREATMENT PATTERNS POST PARP INHIBITOR IN EPITHELIAL OVARIAN CANCER PATIENTS: RESULTS FROM AN AUSTRALIAN, RETROSPECTIVE, MULTI-INSTITUTE COHORT STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, Vol. 30, pp. A166 - A167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000616549600346&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

O'Malley DM; Bookman MA; Moore KN; Fleming GF; Brady MF; Swisher EM; Aghajanian C; Steffensen KD; Friedlander M; Okamoto A; Spirtos NM; Shahin MS; Reid TJ; Sullivan DM; Sehgal V; Ansell PJ; Dinh MH; Coleman RL, 2020, 'Anti-tumor activity of veliparib during combination phase with chemotherapy in velia study', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 159, pp. 52 - 53, http://dx.doi.org/10.1016/j.ygyno.2020.06.110

Kaufman B; Han H; Arun B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla S; Maag D; Feng D; Fages S; Dieras VC, 2020, 'Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S374 - S374, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.427

Dieras V; Arun B; Han HS; Wildiers H; Friedlander M; Ayoub JP; Puhalla S; Hudgens S; Floden L; Khandelwal N; Benjamin K; Kamalakar R; Maag D, 2020, 'Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S348 - S349, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.376

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon T-W; Sonke GS; Lisyanskaya AS; Kim J-H; Abdo Filho E; Vergote I; Rowe P; Pujade-Lauraine E, 2020, 'Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302431&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aghajanian C; Bookman MA; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Sullivan DM; Fallstrom M; Dinh M; Ratajczak C; Coleman RL, 2020, 'PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302501&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Han HS; Arun B; Kaufman B; Wildiers H; Friedlander M; Ayoub J-PM; Puhalla SL; Bach BA; Dudley M; Kundu MG; Maag D; Ratajczak C; Dieras V, 2020, 'Veliparib (V) monotherapy (monoTx) following combination therapy with V plus carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368300309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Puhalla SL; Dieras V; Arun B; Kaufman B; Wildiers H; Han HS; Ayoub J-PM; Stearns V; Yuan Y; Helsten TL; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak C; Ramathal C; Friedlander M, 2020, 'Veliparib (V) monotherapy after progression on placebo (PL) plus carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368300315&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jones T; Spence R; Sandler C; Obermair A; Friedlander M; Mileshkin L; Davis A; Janda M; Eakin E; Barnes E; Beesley V; Gordon L; Brand A; Hayes S, 2020, 'Are The ACSM Exercise Guidelines Safe And Achievable For Women Receiving Chemotherapy For Ovarian Cancer?', in MEDICINE & SCIENCE IN SPORTS & EXERCISE, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 52, pp. 483 - 484, presented at 67th Annual Meeting of the American-College-of-Sports-Medicine (ACSM), ELECTR NETWORK

Li T; Timmins H; McCrary J; Trinh T; Friedlander M; Horvath L; Kiernan M; Goldstein D; Park S, 2020, 'Patient reported outcome scores used in chemotherapy-induced peripheral neuropathy: Defining minimal important differences', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, ELECTR NETWORK, Vol. 25, pp. 481 - 481, presented at Virtual Conference of Peripheral-Nerve-Society, ELECTR NETWORK

Friedlander ML; Hettle R; Parkhomenko E, 2019, 'Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700218&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander ML; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; Disilvestro P, 2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page